Webinars, Pharmaceutical

Aptar Pharma discusses intranasal administration for CNS therapeutics

CNS therapies are a well-defined target for drug repurposing for intranasal administration with a growing track record of success that includes commercialized products for treatment resistant depression and seizures.

This webinar examines the defining benefits of intranasal administration such as high patient acceptability, rapid onset, and the ability to deliver drugs to unconscious patients. The biology of drug delivery for CNS therapeutics is also explored with reference to the benefits of bypassing the blood brain barrier. Off-the-shelf devices for intranasal administration are reviewed and strategies for reformulation – powder or liquid – are considered.

The expert support available from Aptar Pharma, to support all aspects of drug reformulation for intranasal administration, are also discussed.

Watch the webinar
Speaker(s): Dr. Julie D. Suman
25 Feb 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

30 Nov 2022

Drug Repositioning – Benefits and Challenges for Lifecycle Mana...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
24 Nov 2022

Step to Success in Nose-to-Brain Drug Delivery

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
9 Nov 2022

Understanding the Evolution of Intranasal Vaccines

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
7 Nov 2022

Intranasal Delivery of Vaccines Using Thin Film Freeze-Dried Powd...

Publications, Pharmaceutical, Product Solutions, Device Innovations, Market Insights

Read More
1 2 3 18

Request Access

Close

Requesting access to Aptar Pharma discusses intranasal administration for CNS therapeutics.

  • This field is for validation purposes and should be left unchanged.
Back To Top